Chemotherapy and Metformin in Pancreatic Adenocarcinoma and Neuroendocrine Tumors

  • Saira Burney Department of Endocrinology & Metabolism, Services Hospital. Lahore, Pakistan
  • Khadija Irfan Khawaja Department of Endocrinology & Metabolism, Services Hospital. Lahore, Pakistan
  • Muhammad Wasif Saif Tufts Medical Center and Tufts Cancer Center. Boston, MA, USA
  • Faisal Masud King Edward Medical University. Lahore, Pakistan
Keywords: Metformin, Pancreatic Neoplasms, Review, Therapeutics


Pancreatic cancer, despite being a relatively less commonly occurring cancer is among the deadliest ones, leading to a grave prognosis. Surgery stands as the mainstay of treatment of pancreatic cancer but is an option in less than 15% patients owing to the late presentation of the tumor. Chemotherapy offers an important part of treatment but can adversely affect the quality of life because of devastating side effects and has limited survival benefit. Unavailability of effective and less toxic treatment options for pancreatic cancer has prompted the search for new treatment strategies. One such drug being considered for its potential anti-neoplastic role is the time-tested and widely used oral hypoglycemic drug, metformin. Metformin is proposed to target metabolic pathways involved in tumorigenesis, specifically the AMPK-mTOR complex. Epidemiological evidence is mounting in favor of its role in various cancers both for treatment and prophylaxis. Herein, we aim to summarize the epidemiological data on metformin as a potential anti-cancer drug in various cancers followed by a look at some of the abstracts relating to this topic that were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014.

Image: Galega officinalis contains the aminoguanidine or metformin.


Download data is not yet available.


Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M et al. Diabetes and Cancer: a consensus report. Diabetes Care. 2010; 33: 1674-1685. [PMID:20587728]

Handelsman Y, Leroith D, Bloomgarden ZT, Dagogo-Jack S, Einhorn D, Garber AJ, Grunberger G et al. Diabetes and cancer-An AACE/ACE consensus statement. Endocr Pract. 2013; 19(4): 675-693. [PMID:23978590]

Chari ST, Leibson CL, Rabe KG, Timmons LJ, Ransom J, de Andrade M, Petersen GM. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008; 134(1): 95-101. [PMID:18061176]

Cicero, A. F. G, Tartagni, E. and Ertek, S. Metformin and its clinical use: new insights for an old drug in clinical practice. Arch. Med. Sci. 2012; 8: 907-917. [PMID:23185203]

Dowling RJO, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012; 48: R31-R43. [PMID:22355097]

Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330: 1304-5. [PMID:15849206]

Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin area at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009; 32: 1620-1625. [PMID:19564453]

Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol. 2012; 29(2): 1314-27. [PMID:21301998]

Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology. 2009; 137 (2): 482-488. [PMID:19375425]

Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total,colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011; 11: 20. [PMID:21241523]

Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52:1766-1777. [PMID:19572116]

Wilmink J, Kordes S, Zwinderman K, Mathot R, Punt CJA, Richel D. A phase II randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib, and metformin in patients with locally advanced or metastatic pancreatic cancer. J Clin Oncol. 2014; 32 (5 suppl): 4021.

Carvalho A, Ferrari RD, Pfiffer TEF, Alex AK, Nebuloni DR, Carneiro AQ, Capareli FC et al. Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas. J Clin Oncol 2014; 32 (suppl): e15196.

Pusceddu S, Buzzoni R, Giacomelli L, Mazzaferro V, Concas L, Milione M, et al. The impact of metformin on progression-free survival of patients with advanced pancreatic well-differentiated neuroendocrine tumor receiving everolimus plus somatostatin analog treatment. J Clin Oncol. 2014; 32 (suppl): e15172.

Jiralerspong S, Palla SL, Giordano SH, Funda Meric-Bernstam F, Liedtke C, Barnett CM et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009; 27: 3297-3302. [PMID:19487376]

Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res. 2012; 18: 2905-2912. [PMID:22465831]

Galega officinalis contains the aminoguanidine or metformin
How to Cite
BurneyS., KhawajaK., SaifM., & MasudF. (2014). Chemotherapy and Metformin in Pancreatic Adenocarcinoma and Neuroendocrine Tumors. JOP. Journal of the Pancreas, 15(4), 313-316.
Highlights from the “50th ASCO Annual Meeting 2014”. Chicago, IL, USA. May 30 - June 3, 2014

Most read articles by the same author(s)